Related Experiment Video
Updated: Nov 13, 2025
06:38
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.2K
Current and Future Systemic Therapies in Biliary Tract Cancer
Arndt Vogel1, Anna Saborowski1
1Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany.
Visceral Medicine
|March 12, 2021
Summary
Precision medicine, including targeted therapies for specific genetic mutations like IDH1 and FGFR2, is transforming biliary tumor treatment. Early genetic diagnostics are crucial for selecting effective systemic therapies in both adjuvant and palliative settings for these rare cancers.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Biliary tumors are rare but increasing, often diagnosed late, limiting surgical options.
- Current standard palliative care involves gemcitabine and cisplatin chemotherapy.
- Emerging research is expanding first- and second-line systemic treatment strategies.
Purpose of the Study:
- To provide an overview of systemic therapy concepts for biliary malignancies.
- To highlight the role of precision medicine and early tumor genetic diagnostics.
- To discuss targeted therapies for specific patient subgroups.
Main Methods:
- Review of current systemic therapy concepts in adjuvant and palliative settings.
- Analysis of emerging treatment options and targeted therapies.
- Emphasis on the importance of molecular profiling for biliary tract cancers.
Main Results:
- Molecularly targeted therapies are becoming increasingly important for specific patient subgroups.
- Targetable alterations include IDH1 mutations, FGFR2 fusions, HER2/neu amplification, NTRK fusions, and BRAF mutations.
- Precision medicine is poised to significantly impact the therapeutic landscape.
Conclusions:
- Precision medicine will play a pivotal role in treating biliary malignancies.
- Early tumor genetic diagnostics are essential for guiding treatment decisions.
- Considering rare but targetable alterations is critical for optimizing patient outcomes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
02:49Cancer Therapies
9.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.0K
01:27Tumor Immunotherapy
826
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
826
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
284
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
284
01:29Chronic Pancreatitis II: Collaborative Care
170
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
170